Evidence map›Paper›PMID 36402793›Full record

ArticleScientific reports2022

A fluorescent photoimmunoconjugate for imaging of cholesteatoma.

Samuel Early, M Ahsan Saad, Srivalleesha Mallidi, Amer Mansour, Richard Seist, Tayyaba Hasan, Konstantina M Stankovic

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Genetic Discovery Enabled by A Large Language Model.bioRxiv : the preprint server for biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Samuel EarlyDepartment of Otolaryngology - Head and Neck Surgery and Eaton-Peabody Laboratories, Massachusetts Eye and Ear, Boston, MA, USA.
M Ahsan SaadWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.
Srivalleesha MallidiWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.
Amer MansourDepartment of Otolaryngology - Head and Neck Surgery and Eaton-Peabody Laboratories, Massachusetts Eye and Ear, Boston, MA, USA.
Richard SeistDepartment of Otolaryngology - Head and Neck Surgery and Eaton-Peabody Laboratories, Massachusetts Eye and Ear, Boston, MA, USA.
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA.
Konstantina M StankovicDepartment of Otolaryngology - Head and Neck Surgery and Eaton-Peabody Laboratories, Massachusetts Eye and Ear, Boston, MA, USA. kstankovic@stanford.edu.
Massachusetts General Hospital · USHarvard University · USMassachusetts Eye and Ear Infirmary · USStanford University · US

Funding

Mechanisms of sensorineural hearing loss: secreted factorsR01DC015824 · NIDCD · STANFORD UNIVERSITY · PI STANKOVIC, KONSTANTINA M · 2016 to 2020
$2.2M
NIDCD NIH HHS R01 DC015824
6 · The paper itself

Abstract

Cholesteatoma is a potentially serious complication of chronic ear infections and requires surgical intervention for definitive management. Long-term complications include a frequent need for repeat surgical intervention for disease recurrence, and techniques to improve efficacy of single-stage surgery are an important area of continued research. This study investigates a novel application of the photosensitizer immune conjugate (PIC) cetuximab-benzoporphyrin derivative (Cet-BPD) for in vitro localization of human cholesteatoma tissue, coupled with an in vivo safety study for middle ear application of Cet-BPD in a murine model. In fresh human cholesteatoma tissues, Cet-BPD demonstrates selective localization to the hyperplastic squamous cell tissue associated with cholesteatoma, without localizing to other tissues such as middle ear mucosa. Applied to the murine middle ear, Cet-BPD does not demonstrate any deleterious effect on murine hearing when assessed by any of auditory brainstem response (ABR) thresholds, distortion product otoacoustic emission thresholds, or ABR wave I amplitudes. These findings demonstrate the technical promise and encouraging safety profile for the use of PICs for intraoperative localization and treatment of cholesteatoma.

Indexed as

Cholesteatoma, Middle EarAnimalsColoring AgentsDiagnostic ImagingEar, MiddleHearing TestsHumansMiceColoring Agents

Identifiers

PMID36402793
PMCPMC9675863
OpenAlexW4309562620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.